J Pediatr Genet 2021; 10(04): 259-265
DOI: 10.1055/s-0041-1736458
Case-Based Review

A Novel 4q32.3 Deletion in a Child: Additional Signs and the Role of MARCH1

1   Unit of Catania, Institute for Biomedical Research and Innovation, National Council of Research, Catania, Italy
2   Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
,
3   Section of Pediatrics and Child Neuropsychiatry, Unit of Rare Diseases of the Nervous System in Childhood, Department of Clinical and Experimental Medicine, AOU “Policlinico,” PO “G. Rodolico,” University of Catania, Catania, Italy
,
4   Unit of Pediatrics, Neonatology and Neonatal Intensive Care, and Pediatric Emergency, AOU “Policlinico,” PO “San Marco,” University of Catania, Catania, Italy
,
5   Pediatric Clinic, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy
,
6   Pediatric Intensive Care Unit, IRCCS, Bambino Gesù Children's Hospital, Rome, Italy
,
4   Unit of Pediatrics, Neonatology and Neonatal Intensive Care, and Pediatric Emergency, AOU “Policlinico,” PO “San Marco,” University of Catania, Catania, Italy
› Author Affiliations

Abstract

The 4q deletion syndrome is an uncommon condition manifesting with broad clinical expression and phenotypic variability. We report a 5-year-old boy affected by 4q deletion syndrome who showed minor craniofacial features, growth failure, mild developmental delay, severe speech delay, and marked irascibility and aggressivity. Moreover, he showed precocious and crowded primary dentition, digital hyperlaxity, and congenital bilateral adducted thumbs, signs which were previously unreported in the syndrome. The array comparative genomic hybridization analysis revealed a 4q partial terminal deletion of ∼329.6 kb extending from 164.703.186 to 165.032.803 nt, which includes part of MARCH1 (membrane associated ring-CH-type finger 1) gene (OMIM#613331). Same rearrangement was found in his healthy mother. Clinical phenotype of the child and its relationship to the deleted region is presented with a revision of the cases having the same copy number losses from the literature and genomic variant databases.

Ethical Approval

This study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki and was approved by the ethic committee of the University of Catania, Italy (Ethical Committee Catania 1 Clinical Registration n. 95/2018/PO). Informed consent was obtained from parents of the proband.


Authors' Contributions

X.G.P. and P.P. conceived the manuscript. P.P., M.R., and R.F. worked with and helped gather patient data. P.P. and M.R. drafted and redrafted the present manuscript. X.G.P. helped analyze the genetic data and interpreted the literature relevant to the genomic imbalance. All authors read and approved the final manuscript.




Publication History

Received: 31 May 2021

Accepted: 09 September 2021

Article published online:
02 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Ockey CH, Feldman GV, Macaulay ME, Delaney MJ. A large deletion of the long arm of chromosome no. 4 in a child with limb abnormalities. Arch Dis Child 1967; 42 (224) 428-434
  • 2 Golbus MS, Conte FA, Daentl DL. Deletion from the long arm of chromosome 4 (46,XX,4q-) associated with congenital anomalies. J Med Genet 1973; 10 (01) 83-85
  • 3 Townes PL, White M, Di Marzo SV. 4q- syndrome. Am J Dis Child 1979; 133 (04) 383-385
  • 4 Lin AE, Garver KL, Diggans G. et al. Interstitial and terminal deletions of the long arm of chromosome 4: further delineation of phenotypes. Am J Med Genet 1988; 31 (03) 533-548
  • 5 Strehle E-M, Gruszfeld D, Schenk D, Mehta SG, Simonic I, Huang T. The spectrum of 4q- syndrome illustrated by a case series. Gene 2012; 506 (02) 387-391
  • 6 Strehle EM, Ahmed OA, Hameed M, Russell A. The 4q-syndrome. Genet Couns 2001; 12 (04) 327-339
  • 7 Strehle EM, Bantock HM. The phenotype of patients with 4q-syndrome. Genet Couns 2003; 14 (02) 195-205
  • 8 Strehle E-M, Yu L, Rosenfeld JA. et al. Genotype-phenotype analysis of 4q deletion syndrome: proposal of a critical region. Am J Med Genet A 2012; 158A (09) 2139-2151
  • 9 Xu W, Ahmad A, Dagenais S, Iyer RK, Innis JW. Chromosome 4q deletion syndrome: narrowing the cardiovascular critical region to 4q32.2-q34.3. Am J Med Genet A 2012; 158A (03) 635-640
  • 10 Quadrelli R, Strehle EM, Vaglio A. et al. A girl with del(4)(q33) and occipital encephalocele: clinical description and molecular genetic characterization of a rare patient. Genet Test 2007; 11 (01) 4-10
  • 11 Kuldeep CM, Khare AK, Garg A, Mittal A, Gupta L. Terminal 4q deletion syndrome. Indian J Dermatol 2012; 57 (03) 222-224
  • 12 Sandal G, Ormeci AR, Oztas S. De novo terminal 4q deletion syndrome with new ocular findings in Turkish twins: case report. Genet Couns 2013; 24 (02) 217-222
  • 13 Vona B, Nanda I, Neuner C. et al. Terminal chromosome 4q deletion syndrome in an infant with hearing impairment and moderate syndromic features: review of literature. BMC Med Genet 2014; 15: 72
  • 14 Meaux T, Zeringue A, Mumphrey C, Barkemeyer B, Marble M. Bilateral absence of the ulna in 4q terminal deletion syndrome: evidence for a critical region. Clin Dysmorphol 2015; 24 (03) 122-124
  • 15 Lurie IW. A critical region for ulnar defects in patients with 4q deletions may be narrowed. Clin Dysmorphol 2016; 25 (03) 133
  • 16 Tidrenczel Z, Tardy EP, Pikó H. et al. Prenatal diagnosis of 4q terminal deletion and review of the literature. Cytogenet Genome Res 2019; 158 (02) 63-73
  • 17 Ziegler A, Colin E, Goudenège D, Bonneau D. A snapshot of some pLI score pitfalls. Hum Mutat 2019; 40 (07) 839-841
  • 18 Samji T, Hong S, Means RE. The membrane associated RING-CH proteins: a family of E3 ligases with diverse roles through the cell. Int Sch Res Notices 2014; 2014: 637295
  • 19 Lin H, Li S, Shu H-B. The membrane-associated MARCH E3 ligase family: emerging roles in immune regulation. Front Immunol 2019; 10: 1751
  • 20 Galbas T, Raymond M, Sabourin A. et al. MARCH1 E3 ubiquitin ligase dampens the innate inflammatory response by modulating monocyte functions in mice. J Immunol 2017; 198 (02) 852-861
  • 21 Kasherman MA, Premarathne S, Burne THJ, Wood SA, Piper M. The ubiquitin system: a regulatory hub for intellectual disability and autism spectrum disorder. Mol Neurobiol 2020; 57 (05) 2179-2193
  • 22 Cheon S, Kaur K, Nijem N. et al. The ubiquitin ligase UBE3B, disrupted in intellectual disability and absent speech, regulates metabolic pathways by targeting BCKDK. Proc Natl Acad Sci U S A 2019; 116 (09) 3662-3667
  • 23 Xie L, Dai H, Li M. et al. MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways. J Cell Mol Med 2019; 23 (05) 3386-3401
  • 24 Takumi T, Tamada K. CNV biology in neurodevelopmental disorders. Curr Opin Neurobiol 2018; 48: 183-192
  • 25 Falsaperla R, Pappalardo XG, Romano C. et al. Intronic variant in CNTNAP2 gene in a boy with remarkable conduct disorder, minor facial features, mild intellectual disability, and seizures. Front Pediatr 2020; 8: 550